Cargando…
Preventive plasmapheresis for rituximab related flare in cryoglobulinemic vasculitis
INTRODUCTION: Rituximab monotherapy represents the main therapeutic option for cryoglobulinemic vasculitis (CV) with severe organ involvement. However, initial worsening of the CV, known as rituximab-associated CV flare (=CV flare), has been described and are associated with high mortality rates. Th...
Autores principales: | Fornero, Léa, Kanouni, Tarik, Tudesq, Jean-Jacques, Pochard, Camille, Verot, Pauline, Renier, Wendy, Gabellier, Ludovic, Cartron, Guillaume, Guilpain, Philippe, Herbaux, Charles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975310/ https://www.ncbi.nlm.nih.gov/pubmed/36874399 http://dx.doi.org/10.1016/j.jtauto.2023.100194 |
Ejemplares similares
-
Rituximab-Associated Flare of Cryoglobulinemic Vasculitis
por: Sy-Go, Janina Paula T., et al.
Publicado: (2021) -
A Flare of Hepatitis C Virus-Associated Cryoglobulinemic Vasculitis After COVID-19
por: Hamazaki, Kenya, et al.
Publicado: (2022) -
Rituximab for Sjögren syndrome–associated type II mixed cryoglobulinemic cerebral vasculitis
por: Lioger, Bertrand, et al.
Publicado: (2016) -
Rare manifestations of cryoglobulinemic vasculitis: a case report
por: Leleux, Charlotte, et al.
Publicado: (2023) -
Non HCV-Related Mixed Cryoglobulinemic Vasculitis With Biopsy-Proven Renal Involvement: The Effects of Rituximab
por: Fenoglio, Roberta, et al.
Publicado: (2022)